Progress in Cleveland Clinic–Nimbus Total Artificial Heart Development
1994; Lippincott Williams & Wilkins; Volume: 40; Issue: 3 Linguagem: Inglês
10.1097/00002480-199407000-00049
ISSN1538-943X
AutoresHiroaki Harasaki, Kiyotaka Fukamachi, Alex Massiello, Jifeng Chen, Stephen Himley, Fumio Fukumura, Kazuhiro Muramoto, Satoshi Niu, K. Wika, Charles R. Davies, Patrick M. McCarthy, R Kiraly, D. Thomas, Thomas C. Rintoul, John C. Carriker, Timothy Maher, K. Butler,
Tópico(s)Advanced battery technologies research
ResumoA totally implantable, Cleveland Clinic-Nimbus total artificial heart (TAH) uses electrohydraulic energy conversion and an automatic left master-alternate mode control scheme, with a filling sensitivity of 1.0 l/min/mmHg and a maximum output of 9.5 l/min. The TAHs were tested in 12 calves for 1-120 days with normal major organ and blood cell function. Post-operative suppression of platelet aggregation recovered by the second post-operative week. The gelatin-coated pump surface generally was clean without any anticoagulants and free from infection. Embolism, which occurred in two cases, was caused by complications attributable to fungal infection in a Dacron graft and by thrombus formed around a jugular vein catheter. A system with a hybridized microcircuit controller in the interventricular space has been tested successfully in the three most recent cases, with a peak device surface temperature elevation of 6.5 degrees C. Heat effects were confined to the tissues immediately adjacent to the hottest spots. The carbon fiber-reinforced epoxy housing and 60 ml butyl rubber compliance chamber showed good tissue compatibility with a thin, fibrous tissue capsule. The transcutaneous energy transmission system and the internal battery functioned well as designed in the most recent animal implant.
Referência(s)